GRCE on Nasdaq
Grace Therapeutics, Inc.
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with SIGA TECHNOLOGIES INC, Zymeworks or ZEVRA THERAPEUTICS, INC., or pick any stock.
- TickerGRCE on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersPrinceton, New Jersey1
- Incorporated inDE3
- Business address103 Carnegie Center, Suite 300, Princeton, Nj 085403
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Research and development6¢$5.6M
- Other costs94¢$93.8M
- Income tax1¢$648.0K
Out of $100.0M in revenue.57 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Research and development expenses | $2.4M | $9.5M |
| General and administrative expenses | $8.7M | $7.2M |
| Loss from operating activities | -$11.1M | -$16.7M |
| Foreign exchange loss | -$1.0K | -$17.0K |
| Change in fair value of derivative warrant liabilities | $900.0K | $3.2M |
| Interest and other income, net | $685.0K | $711.0K |
| Total other income, net | $1.6M | $3.9M |
| Loss before income tax benefit | -$9.5M | -$12.8M |
| Income tax benefit | $1.7M | $3.2M |
| Net loss | -$7.8M | -$9.6M |
| Total comprehensive loss | -$7.8M | -$9.6M |
| Basic loss per share (in Dollars per share) | -$0.47 | -$0.79 |
| Diluted loss per share (in Dollars per share) | -$0.47 | -$0.79 |
| Weighted average number of shares outstanding, basic (in Shares) | 16.5M shares | 12.1M shares |
| Weighted average number of shares outstanding, diluted (in Shares) | 16.5M shares | 12.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.0M | $22.1M | |
| Receivables | $20.0K | $126.0K | |
| Prepaid expenses | $383.0K | $453.0K | |
| Total current assets | $17.4M | $22.7M | |
| Equipment, net | $8.0K | $15.0K | |
| Intangible assets | $41.1M | $41.1M | |
| Goodwill | $8.1M | $8.1M | $8.1M |
| Total assets | $66.7M | $72.0M | |
| Trade and other payables | $2.1M | $1.9M | |
| Total current liabilities | $2.1M | $1.9M | |
| Derivative warrant liabilities | $0 | $1.1M | $4.4M |
| Deferred tax liability | $612.0K | $2.3M | |
| Total liabilities | $2.8M | $5.4M | |
| Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2026 and 2025 | $0 | $0 | |
| Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,024,026 and 13,718,106 shares issued and outstanding as of March 31, 2026 and 2025, respectively | $1.0K | $1.0K | |
| Additional paid-in capital | $298.4M | $293.3M | |
| Accumulated other comprehensive loss | -$6.0M | -$6.0M | |
| Accumulated deficit | -$228.5M | -$220.7M | |
| Total stockholders equity | $63.9M | $66.6M | $61.7M |
| Total liabilities and stockholders equity | $66.7M | $72.0M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) (in Shares) | 100.0M shares | 100.0M shares | |
| Shares issued (in Shares) | 16.0M shares | 13.7M shares | |
| Shares outstanding (in Shares) | 16.0M shares | 13.7M shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.0M | $22.1M | |
| Receivables | $20.0K | $126.0K | |
| Prepaid expenses | $383.0K | $453.0K | |
| Total current assets | $17.4M | $22.7M | |
| Equipment, net | $8.0K | $15.0K | |
| Intangible assets | $41.1M | $41.1M | |
| Goodwill | $8.1M | $8.1M | $8.1M |
| Total assets | $66.7M | $72.0M | |
| Trade and other payables | $2.1M | $1.9M | |
| Total current liabilities | $2.1M | $1.9M | |
| Derivative warrant liabilities | $0 | $1.1M | $4.4M |
| Deferred tax liability | $612.0K | $2.3M | |
| Total liabilities | $2.8M | $5.4M | |
| Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2026 and 2025 | $0 | $0 | |
| Common stock, $0.0001 par value per share; 100,000,000 authorized; 16,024,026 and 13,718,106 shares issued and outstanding as of March 31, 2026 and 2025, respectively | $1.0K | $1.0K | |
| Additional paid-in capital | $298.4M | $293.3M | |
| Accumulated other comprehensive loss | -$6.0M | -$6.0M | |
| Accumulated deficit | -$228.5M | -$220.7M | |
| Total stockholders equity | $63.9M | $66.6M | $61.7M |
| Total liabilities and stockholders equity | $66.7M | $72.0M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) (in Shares) | 100.0M shares | 100.0M shares | |
| Shares issued (in Shares) | 16.0M shares | 13.7M shares | |
| Shares outstanding (in Shares) | 16.0M shares | 13.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net loss | -$7.8M | -$9.6M |
| Depreciation expense | $7.0K | $7.0K |
| Loss on disposal | $0 | $2.0K |
| Stock-based compensation | $798.0K | $730.0K |
| Change in fair value of derivative warrant liabilities | -$900.0K | -$3.2M |
| Deferred income tax benefit | -$1.7M | -$3.2M |
| Receivables | $106.0K | $596.0K |
| Prepaid expenses | $70.0K | -$170.0K |
| Trade and other payables | $543.0K | -$84.0K |
| Net cash used in operating activities | -$8.9M | -$14.9M |
| Maturity of short-term investments | $0 | $15.0K |
| Purchase of short-term investments | $0 | -$15.0K |
| Net cash provided by investing activities | $0 | $0 |
| Gross proceeds from issuance of common stock and warrants from private placement | $0 | $15.0M |
| Stock issuance costs | -$327.0K | -$967.0K |
| Proceeds from issuance of common stock from common warrant exercise | $4.0M | $0 |
| Net cash provided by financing activities | $3.7M | $14.0M |
| Net decrease in cash and cash equivalents | -$5.2M | -$872.0K |
| Issuance costs in accounts payable | $0 | $327.0K |
| Settlement of derivative warrant liability | $241.0K | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Grace Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief operating officer
- Chief executive officerPrashant Kohli Jul 18, 2023 to now14
- Chief executive officerJanelle D'Alvise Apr 1, 2020 to Jun 23, 202215
- PresidentJanelle D'Alvise Apr 1, 2020 to Jun 23, 202215
- PresidentJean-Francois Boily Apr 1, 2020 to Apr 1, 202016
- Chief operating officerGeorge Kottayil Nov 23, 2021 to Jun 23, 202217
- Chief operating officerPierre Lemieux Apr 1, 2020 to Jun 23, 202218
Board members and other officers (16)
- Vice President, FinanceRobert J. Delaversano Jan 8, 2024 to now19
- VP Program ManagementAmresh Kumar May 18, 2023 to now20
- VP Clinical OperationsCarrie D'Andrea May 18, 2023 to now21
- Chief Medical OfficerR. Loch Macdonald May 26, 2023 to now22
- CCOPrashant Kohli Sep 16, 2022 to Sep 16, 202223
- CHIEF COMMERCIAL OFFICERBrian J. Groch Apr 1, 2020 to Apr 1, 202024
- Board memberA. Brian Davis Oct 20, 2023 to now25
- Board memberEdward Neugeboren Oct 20, 2023 to now26
- Board memberGeorge Kottayil Oct 20, 2023 to now27
- Board memberPrashant Kohli Dec 20, 2023 to now28
- Board memberMichael Derby Apr 1, 2022 to Jul 18, 202329
- Board memberVimal Kavuru Sep 28, 2021 to now30
- Board memberDonald Olds Apr 1, 2020 to Sep 5, 202331
- Board memberJanelle D'Alvise Apr 1, 2020 to Jun 23, 202215
- Board memberRoderick Noel Carter Apr 1, 2020 to Nov 16, 202132
- Board memberJohn Canan Feb 22, 2017 to Sep 30, 202233
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Interim Chief Financial OfficerBrian Ford named Oct 10, 202334
Former names
- Acasti Pharma Inc.Sep 2, 2008 to Oct 25, 20243
Timeline
Filings
229 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 68 major events, 79 insider forms, 19 large holders, 3 private raises, 37 other. The latest 20:
- Oct 13, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 1, 20264 EDGAR
- Oct 1, 20264/A EDGAR
- Sep 23, 20264 EDGAR
- Sep 21, 20264 EDGAR
- Sep 21, 20264 EDGAR
- Sep 21, 20264 EDGAR
- Sep 21, 20264 EDGAR
- Sep 18, 20268-K EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Aug 31, 2026EFFECT EDGAR
- Aug 24, 2026S-3 EDGAR
- Aug 19, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Opaleye Management Inc.10% owner | Buy | 5,318 | $2.10 | $11.2K | Form 4 |
| Sep 21, 2026 | Opaleye Management Inc.10% owner | Buy | 9,771 | $2.10 | $20.5K | Form 4 |
| Sep 9, 2026 | Opaleye Management Inc.10% owner | Buy | 5,836 | $2.09 | $12.2K | Form 4 |
| Sep 9, 2026 | Kohli PrashantChief Executive Officer | Buy | 100,000 | $2.14 | $214.0K | Form 4 |
| Sep 8, 2026 | Opaleye Management Inc.10% owner | Buy | 9,393 | $2.10 | $19.7K | Form 4 |
| Aug 14, 2026 | Opaleye Management Inc.10% owner | Buy | 11,608 | $2.09 | $24.3K | Form 4 |
| Sep 25, 2023 | Kavuru VimalDirector | Buy | 676,371 | $1.85 | $1.3M | Form 4 |
| Aug 31, 2023 | Olds DonaldDirector | Buy | 381 | $2.05 | $781 | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ADAR1 Capital Management, LLCSCHEDULE 13G/A, 7 filings Jul 10, 2024 to Aug 14, 202635
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 4 filings May 15, 2025 to Aug 14, 202636
- Opaleye Management Inc.SCHEDULE 13G, 1 filing Aug 7, 202637
- Orin HirschmanSCHEDULE 13G/A, 5 filings Apr 9, 2024 to Apr 27, 202638
- Bank of AmericaSC 13G/A, 2 filings Feb 13, 2024 to Nov 14, 202439
Money raised
Private offerings the company reported to the SEC on Form D.
- Aug 4, 2026Raised $10 million in a private offering of equity Form D: 9 investors so far Form D
- Feb 10, 2025Raised $15 million in a private offering of equity Form D: $30 million offered in all Form D
- Sep 25, 2023Raised $7.5 million in a private offering of equity Form D: $15.1 million offered in all Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 33. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARJean-Francois Boily, President
- 17
- 18
- 19
- 20SEC EDGARAmresh Kumar, VP Program Management
- 21
- 22
- 23SEC EDGARPrashant Kohli, CCO
- 24
- 25SEC EDGARA. Brian Davis, Board member
- 26SEC EDGAREdward Neugeboren, Board member
- 27SEC EDGARGeorge Kottayil, Board member
- 28SEC EDGARPrashant Kohli, Board member
- 29SEC EDGARMichael Derby, Board member
- 30SEC EDGARVimal Kavuru, Board member
- 31SEC EDGARDonald Olds, Board member
- 32SEC EDGARRoderick Noel Carter, Board member
- 33SEC EDGARJohn Canan, Board member
- 34
- 35
- 36
- 37
- 38
- 39